Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies

被引：28
|
作者：
Page, M. M. [1 ]
Ekinci, E. I. [2 ,4 ,5 ]
Jones, R. M. [3 ,4 ]
Angus, P. W. [3 ,4 ]
Gow, P. J. [3 ,4 ]
O'Brien, R. C. [2 ,4 ]
机构：
[1] Royal Perth Hosp, Lipid Disorders Clin, Perth, WA 6000, Australia
[2] Austin Hlth, Austin Hlth Endocrine Ctr, Melbourne, Vic, Australia
[3] Austin Hlth, Liver Transplant Unit, Melbourne, Vic, Australia
[4] Univ Melbourne, Dept Med, Melbourne, Vic, Australia
[5] Menzies Sch Hlth Res, Darwin, NT, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2014年 / 44卷 / 06期
基金：
澳大利亚国家健康与医学研究理事会;
关键词：
familial hypercholesterolaemia; liver transplantation; LDL-apheresis; mipomersen; lomitapide; HEART; LIPOPROTEINS; SURGERY; PATIENT; BYPASS;
D O I：
10.1111/imj.12444
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Homozygous familial hypercholesterolaemia (FH) causes severe premature coronary artery disease because of very high levels of low density lipoprotein (LDL)-cholesterol. Standard lipid-lowering drugs and LDL-apheresis may not be sufficiently effective. Liver transplantation replaces defective LDL receptors and vastly improves the lipid profile, and we present the first report of an Australian adult to receive this treatment. Emerging drug treatments for FH may be alternatives to LDL-apheresis and transplantation, but long-term safety and efficacy data are lacking for all of these options.
引用
收藏
页码：601 / 604
页数：4
相关论文
共 50 条
  • [1] Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies (vol 44, pg 601, 2014)
    Page, M. M.
    Ekinci, E. I.
    Jones, R. M.
    Angus, P. W.
    Gow, P. J.
    O'Brien, R. C.
    INTERNAL MEDICINE JOURNAL, 2014, 44 (10) : 1050 - 1050
  • [2] Lipid-lowering treatment for homozygous familial hypercholesterolaemia
    Santos, Raul D.
    LANCET, 2013, 381 (9873): : 1182 - 1182
  • [3] Lipid-lowering treatment for homozygous familial hypercholesterolaemia reply
    Cuchel, Marina
    Rader, Daniel J.
    LANCET, 2013, 381 (9873): : 1183 - 1183
  • [4] STATIN AND OTHER LIPID-LOWERING THERAPY AND PREGNANCY OUTCOMES IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA
    Botha, Theunis C.
    Raal, Frederick J.
    Blom, Dirk J.
    Pilcher, Gillian J.
    Wolmarans, Karen
    ATHEROSCLEROSIS SUPPLEMENTS, 2018, 32 : 131 - 131
  • [5] 'Keep on keeping on': persistence with lipid-lowering treatment in familial hypercholesterolaemia
    Hegele, Robert A.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 30 (04) : 318 - 319
  • [6] Emerging Lipid-Lowering Therapies in Secondary Prevention
    Mahtta, Dhruv
    Virani, Salim S.
    Bavry, Anthony A.
    CURRENT CARDIOVASCULAR RISK REPORTS, 2019, 13 (06)
  • [7] Emerging Lipid-Lowering Therapies in Secondary Prevention
    Dhruv Mahtta
    Salim S. Virani
    Anthony A. Bavry
    Current Cardiovascular Risk Reports, 2019, 13
  • [8] Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies
    Botha, Theunis C.
    Pilcher, Gillian J.
    Wolmarans, Karen
    Blom, Dirk J.
    Raal, Frederick J.
    ATHEROSCLEROSIS, 2018, 277 : 502 - 507
  • [9] Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
    Hindi, Nagham N.
    Alenbawi, Jamil
    Nemer, Georges
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (09):
  • [10] Remnant cholesterol in the era of intensive lipid-lowering therapies
    Wadstrom, Benjamin N.
    Wulff, Anders B.
    Pedersen, Kasper M.
    Nordestgaard, Borge G.
    EUROPEAN HEART JOURNAL, 2023, 44 (36) : 3483 - 3483
12345